StockData
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc. (SPRB) stock

SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.84+0.35 (+0.86%)

Close on Nov 18, 2026Market cap $117.38MP/E –Yield –

Spruce Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Spruce Biosciences's free cash flow for the twelve months ending Dec 31, 2024 was -$55.96M. For fiscal 2024 it was -$55.96M. The highest annual figure on record is -$12.62M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$55.96M–
FY2023Dec 31, 2023-$33.28M–
FY2022Dec 31, 2022-$41.69M–
FY2021Dec 31, 2021-$35.97M–
FY2020Dec 31, 2020-$27.59M–
FY2019Dec 31, 2019-$12.62M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.26M–
Q1 FY2026Mar 31, 2026-$8.74M–
Q2 FY2025Jun 30, 2025-$8.83M–
Q1 FY2025Mar 31, 2025-$12.73M–
Q4 FY2024Dec 31, 2024-$20.68M–
Q4 FY2023Dec 31, 2023-$11.21M–
Q3 FY2023Sep 30, 2023-$12.28M–
Q4 FY2022Dec 31, 2022-$11.74M–
Q3 FY2022Sep 30, 2022-$8.58M–
Q4 FY2021Dec 31, 2021-$9.81M–
Q3 FY2021Sep 30, 2021-$7.66M–
Q2 FY2021Jun 30, 2021-$9.70M–
Q1 FY2021Mar 31, 2021-$8.81M–
Q4 FY2020Dec 31, 2020-$9.29M–
Q3 FY2020Sep 30, 2020-$7.64M–
Q4 FY2019Dec 31, 2019-$2.91M–

More Spruce Biosciences figures

See a number that looks wrong?